Therapeutics News and Research

RSS

Medical liability concerns lead to overprescription of antibiotics

A new study led by a team of researchers at New York Medical College suggests that that medical liability concerns may be playing a role in the increase of MRSA in healthcare settings by encouraging clinicians to prescribe antibiotics more often and more broadly than clinical circumstances and evidence-based guidelines warrant. The study appeared in the September-October issue of the American Journal of Therapeutics.

19 Dec 2009

Leerink Swann announces availability of its 2010 healthcare investment outlook report

Leerink Swann, the leading healthcare-focused investment banking firm, today announced the availability of the firm’s 2010 healthcare investment outlook report.

18 Dec 2009

Opexa Therapeutics completes registered direct offering

Opexa Therapeutics, Inc., a company developing Tovaxin®, a novel T-cell therapy for multiple sclerosis (MS), today announced that it has completed its registered direct offering with several institutional investors to sell 2,550,000 units, each unit consisting of one share of Opexa common stock, a five-year Series

18 Dec 2009

Vion Pharmaceuticals files for bankruptcy

VION PHARMACEUTICALS, INC., a pharmaceutical company focused on the development of novel cancer therapeutics, announced that it had voluntarily filed for bankruptcy under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware.

18 Dec 2009

Liquidia Technologies to receive $3 million in funding from NIST

Liquidia Technologies today announced it will receive approximately $3 million in funding from the U.S. Commerce Department’s National Institute of Standards and Technology (NIST) to further develop and scale-up the company’s PRINT manufacturing process.

18 Dec 2009

2010 Dr. Paul Janssen Award for Biomedical Research open for nomination

The Dr. Paul Janssen Award for Biomedical Research has opened the 2010 call for nominations. The $100,000 Award recognizes individuals whose efforts have made significant transformational contributions towards the improvement of human health. Nomination forms are available at pauljanssenaward.com and will be accepted until February 15, 2010.

18 Dec 2009

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Regulus Therapeutics Inc., founded by Alnylam Pharmaceuticals, Inc. and Isis Pharmaceuticals, Inc., announced today that it has obtained exclusive rights from the California Institute of Technology to inventions made in the laboratory of David Baltimore, Ph.D. covering methods and compositions for modulating microRNA-146 and microRNA-155.

18 Dec 2009

Phase 2 clinical study of STA-9090 in NSCLC initiated

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it has initiated a Phase 2 clinical study of STA-9090 in non-small cell lung cancer (NSCLC).

18 Dec 2009

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Arno Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing oncology therapeutics, today announced the dosing of the first patient in a Phase II clinical study of its third-generation camptothecin compound, AR-67, in patients with Glioblastoma Multiforme (GBM), an aggressive form of brain cancer.

17 Dec 2009

Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts

NovaBay Pharmaceuticals, Inc., a clinical stage biopharmaceutical company creating a new class of anti-infectives for treating multi-drug resistant pathogens, announced today that effective immediately, its partner, Alcon Inc. has increased its on-going financial support of the company's research and development efforts by more than $2 million per year. The additional funding is expected to enhance NovaBay's pre-clinical and clinical development programs in the areas of eye, ear and sinus infections, as well as contact lens solutions.

17 Dec 2009

Cubist Pharmaceuticals acquires Calixa Therapeutics

Cubist Pharmaceuticals, Inc., a leading acute care therapeutics company has completed its previously announced acquisition of Calixa Therapeutics Inc.,

17 Dec 2009

Silence Therapeutics and Intradigm merge to form RNAi

The Boards of Silence Therapeutics plc and Intradigm Corporation are delighted to announce the merger of their businesses to form a leading company in the field of RNAi (RNA interference).

17 Dec 2009

St. Jude Medical applauds the updated level of evidence for FFR-guided treatment

St. Jude Medical, Inc. applauds the updated level of evidence for Fractional Flow Reserve (FFR)-guided treatment in the Guidelines on Percutaneous Coronary Intervention (PCI).

17 Dec 2009

ODAC to review Cell Therapeutics' NDA for pixantrone

Cell Therapeutics, Inc. (CTI) announced today that on February 10, 2010 the U.S. Food and Drug Administration's Oncologic Drugs Advisory Committee (ODAC) will review the New Drug Application (NDA) for pixantrone for the treatment of relapsed/refractory aggressive non-Hodgkin's lymphoma (NHL).

17 Dec 2009

HFU increases mortality among diabetics, says report

Cardium Therapeutics today reported on recent clinical findings published in the December issue of Diabetes Care showing an increase in mortality in diabetic patients with a history of foot ulcer (HFU) compared with diabetic patients without HFU and with non-diabetic patients.

17 Dec 2009

Thermo Fisher Scientific selected as NCS biological and environmental sample repository partner

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has been selected as the National Children’s Study (NCS) biological and environmental sample repository partner. The study examines the effects of environmental influences on the health and development of 100,000 children across the United States, following them from before birth until age 21.

From Thermo Fisher Scientific Inc. 17 Dec 2009

Ivy Foundation awards nearly $10M for new patient-focused brain cancer research projects

Today, the Ben and Catherine Ivy Foundation (Ivy Foundation), announced that it is funding roughly $10 million for four new patient-focused research projects. As with all Ivy Foundation awards, these projects focus on improving the survival and quality of life for people with brain tumors but also specifically address new strategies to improve treatment development.

16 Dec 2009

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Makefield Therapeutics, Inc., an emerging therapeutics company, today announced that it has obtained an exclusive license from Albert Einstein College of Medicine of Yeshiva University to patent applications covering Makefield's biodegradable Hybrid Nanoparticles™, a versatile new drug delivery platform.

16 Dec 2009

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Onset Therapeutics, a specialty pharmaceutical company focused in dermatology, today announced positive results from a skin moisturization study that compared the Company’s recently launched BenzEFoam™ (benzoyl peroxide 5.3%) Emollient Foam to a market leading combination gel containing clindamycin 1% - benzoyl peroxide 5%. BenzEFoam™ Emollient Foam is indicated for the topical treatment of mild to moderate acne vulgaris and is the first prescription foam formulation containing benzoyl peroxide as the active ingredient.

16 Dec 2009

Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has published an exclusive interview with the CEO of Novelos Therapeutics, Inc., Harry S. Palmin.

16 Dec 2009

Therapeutics News and Research

Medical liability concerns lead to overprescription of antibiotics

Leerink Swann announces availability of its 2010 healthcare investment outlook report

Opexa Therapeutics completes registered direct offering

Vion Pharmaceuticals files for bankruptcy

Liquidia Technologies to receive $3 million in funding from NIST

2010 Dr. Paul Janssen Award for Biomedical Research open for nomination

Regulus Therapeutics wins exclusive rights to modulate microRNAs

Phase 2 clinical study of STA-9090 in NSCLC initiated

Arno Therapeutics announces dosing of first patient in Phase II clinical study of AR-67

Alcon increases its financial support for NovaBay Pharmaceuticals' research and development efforts

Cubist Pharmaceuticals acquires Calixa Therapeutics

Silence Therapeutics and Intradigm merge to form RNAi

St. Jude Medical applauds the updated level of evidence for FFR-guided treatment

ODAC to review Cell Therapeutics' NDA for pixantrone

HFU increases mortality among diabetics, says report

Thermo Fisher Scientific selected as NCS biological and environmental sample repository partner

Ivy Foundation awards nearly $10M for new patient-focused brain cancer research projects

Makefield Therapeutics to patent applications covering its Hybrid Nanoparticle drug delivery platform

Positive results from Onset Therapeutics' BenzEFoam Emollient Foam skin moisturization study

Patients involved in Novelos Therapeutics' pivotal Phase III trial live longer than expected

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News